FAP and lung cancer: Supporting this concept, VbP (Talabostat; PT-100; BXCL-701), which exerts potent inhibition of DPP9 and DPP8 and moderate inhibition of DPP4 and FAP, has been shown to lessen tumor burden in lung cancer and sarcoma models [57,58,59].